RxDoctor Payments Data

Lisa Janosik

Family · Nanty Glo, PANPI 1023475944

Payments from drug & device makers

$13,308in general payments, 2019–2025

Across 903 payments — averaging $14.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Pfizer$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$939
  • Merck$635
  • plus $6K from 40 others

What the payments were for

  • Food & beverage$13,296100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,308 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$26,088
Medicare patients
106
Services billed
403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter111$84,608
OzempicSemaglutide58$65,760
TrulicityDulaglutide59$64,337
MounjaroTirzepatide45$61,932
JardianceEmpagliflozin40$41,411
EliquisApixaban33$29,868
EntrestoSacubitril/Valsartan31$25,060
XareltoRivaroxaban26$18,875
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$12,993
LinzessLinaclotide24$12,761
MyrbetriqMirabegron21$10,168
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,239
Emgality PenGalcanezumab-Gnlm11$7,561
Atorvastatin Calcium373$5,715
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$5,390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$939$126,270104 claims
GSKTrelegy Ellipta, Anoro Ellipta$368$97,601137 claims
Novo NordiskOzempic$1,091$65,76058 claims
Boehringer IngelheimJardiance, Synjardy Xr$492$44,81651 claims
PfizerEliquis$1,070$29,86833 claims
NovartisEntresto$430$25,06031 claims
Johnson & JohnsonXarelto$250$18,87526 claims
AbbVieLinzess$2,500$12,76124 claims
Astellas Pharma US IncMyrbetriq$121$10,16821 claims
AstraZenecaBreztri Aerosphere$1,019$8,23913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Nanty Glo

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →